<DOC>
	<DOCNO>NCT02719639</DOCNO>
	<brief_summary>Real-world data effect fixed-dose combination Long-acting beta agonist + long-acting antimuscarinic agent ( LABA+LAMA ) therapy tiotropium olodaterol administer single device , COPD patient need treatment two long-acting bronchodilator , available . This self-controlled study design enrol consent COPD patient treat Spiolto Respimat accord approve Summary Product Characteristics ( SmPC ) .</brief_summary>
	<brief_title>OTIVACTO Regional Center Vienna ( RCV ) Non-Interventional Study ( NIS )</brief_title>
	<detailed_description>Purpose : Study Design :</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Inclusion criterion : 1 . Written inform consent prior participation 2 . Female male patient equal 40 year age 3 . Patients diagnose COPD require longacting dual bronchodilation ( LAMA + LABA ) treatment accord approve Spiolto Respimat Summary Product Characteristics ( SmPC ) chronic obstructive pulmonary disease ( COPD ) Global Initiative Chronic Obstructive Lung Disease ( GOLD ) guideline recommendation Exclusion criterion : 1 . Patients contraindication accord Spiolto Respimat SmPC 2 . Patients treat LABA/LAMA combination ( free fix dose ) previous 6 month 3 . Patients continue LABAICS ( inhale corticosteroid ) treatment additionally treat Spiolto Respimat order avoid double dose longacting betaagonists 4 . Patients followup possible enrol site plan study period approx . 6 week 5 . Pregnancy lactation 6 . Patients currently list lung transplantation 7 . Current participation clinical trial noninterventional study drug device</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>